Skip to Main Content
CWRU Links
Case Comprehensive Cancer Center

Case CCC Funding Opportunities

Case CCC Funding Opportunities

Opportunities for Pilot Projects in Cancer Immunotherapy

DEADLINE: Friday, June 23, 2017

A major area of the Case Comprehensive Cancer Center (Case CCC) strategic plan at Case Western Reserve University is to promote and increase institution-wide capacity and competitiveness in the development and application of cancer immunotherapy. Recent advances in the understanding of cancer immunobiology, the elaboration of molecular and cellular signaling mechanisms between tumor cells and host-derived stromal and immune components in the tumor microenvironment, and numerous technical advances in the design and application of novel cell-based, antibody-based or small-molecule-based engineered immunotherapeutic products have propelled cancer immunotherapy forward as an exciting and highly-studied area of clinical therapeutic development. Through philanthropic funds made available to the Case Comprehensive Cancer Center, applications for collaborative pilot projects are requested from investigators focused on the understanding of cancer immunology and the investigation of novel immunotherapy approaches. The main goal of this RFA is to stimulate novel research designed to take maximum advantage of new scientific discoveries and technologies and contribute to advances in cancer immunotherapy. To enhance the development of Immune Monitoring capacity within the Case Comprehensive Cancer Center, proposals that emphasize the use of multi-parameter flow cytometry, multi-spectral immunohistochemistry, muti-omics and/or tissue repositories are particularly sought after.

This announcement seeks projects that involve new research collaborations or leverage existing studies among members of the Hematopoietic and Immune Cancer Biology Program, Tumor Immunology & Immunotherapy Focus Group, or between members of these programs and collaborators from another scientific program of the Cancer center. The expectation of this pilot RFA is to generate novel concepts and data with a high likelihood of subsequent successful, collaborative extramural grant funding. A second goal of this RFA is to enhance existing Immune Monitoring capacity (e.g. multi-parameter flow cytometry) or to demonstrate the utility of less-developed Immune Monitoring capability at the Cancer Center (e.g. multi-spectral tissue immunohistochemistry) with approved outside entity.

Areas of inquiry can include (but are not limited to):

  • Characterization and discovery of cellular and molecular mechanisms of immune evasion and/or anti-tumor immune response in pre-clinical or clinical models.
  • Discovery, development and validation of novel tumor immunotherapeutic targets and/or biomarkers of immune response to cancer immunotherapy.
  • Correlative immunological characterization of clinical specimens from existing cancer immunotherapy clinical trials being conducted at Case Comprehensive Cancer Center.

Funding Criteria:

  • Up to 2 pilots of $75,000 each or 3 pilots of $50,000 will be awarded.
  • Strong collaborative investigative teams of Case Comprehensive Cancer Center members that clearly demonstrate programmatic alignment.
  • Highly innovative and impactful projects.
  • All materials to complete the project should be in-hand or readily available. For example, tissue-based research will require an approved IRB protocol and patient cohort studies must have already recruited the cohort. Collection of new patient cohorts is not responsive to this RFA.
  • Projects must have a high likelihood of subsequent national-level funding.
  • While investigators can be collaborators on multiple applications, only one application will be accepted per lead PI.
  • All funds for core facilities must use Case Comprehensive Cancer Center cores, when available, or existing cores at institutions outside Cleveland with prior approval by TI&I leadership.
  • Letter of collaboration from one of the following flow cytometry core directors needs to be provided for proposals involving multi-parameter flow cytometry: Rafick Sekaly-Pierre (rafick.sekaly@case.edu); James Jacobberger (james.jacobberger@case.edu); Howard Meyerson (howard.meyerson@uhhospitals.org); Scott Sieg (sfs2@case.edu)
  • For proposals requiring multi-spectral IHC analyses, please discuss with Alex Huang (alex.y.huang@case.edu) to connect with pre-approved outside expertise.

View detailed instructions: [immunotherapy-instructions-2017]

Contact casecccpilots@case.edu or Megan Kilbane at 216.286.4440 with any questions.

Opportunities for Pilot Projects in GU Malignancies

DEADLINE: Friday, June 23, 2017

The Case Comprehensive Cancer Center will provide seed money to foster collaborations and to promote and increase institution-wide capacity and competitiveness in the investigation of genitourinary malignancies. Based on the quality of the applications, up to 2 pilots of up to $75,000 will be awarded to investigators who intend to gather preliminary data to be used in seeking future extramural and nationally-competitive funding. Case Comprehensive Cancer Center members with a faculty appointment at all levels are encouraged to apply (applicants must be eligible to apply as PIs of nationally competitive research grants - postdoctoral fellows, graduate students and research associates are not eligible to apply for these pilot funds). Proposals from both junior and senior investigators are encouraged. Demonstrated feasibility to develop into a externally funded research project within two years and a plan for competing for such funding is a required component of the pilot application. Projects submitted for review must be distinct from currently funded research and describe new projects that could not be achieved without the collaboration and pilot funds.

Areas of inquiry can include (but are not limited to): 

  • Prostate cancer biology including, but not limited to, AR signaling, genetic drivers and hormone therapy resistance
  • Kidney cancer including, but not limited to, immunotherapy and signaling
  • Bladder cancer including, but not limited to, immunotherapy and cell signaling

Funding Criteria:

  • Up to 2 pilots of $75,000 will be awarded.
  • Strong collaborative investigative teams of Case Comprehensive Cancer Center members that clearly demonstrate programmatic alignment (letter from a GU Program Leader indicating alignment is required for the application to be responsive to this RFA).
  • Highly innovative and impactful projects.
  • All materials to complete the project should be in-hand or readily available. For example, tissue-based research will require an approved IRB protocol and patient cohort studies must have already recruited the cohort. Collection of new patient cohorts is not responsive to this RFA.
  • Projects must have a high likelihood of subsequent national-level funding.
  • While investigators can be collaborators on multiple applications, only one application will be accepted per lead PI.
  • All funds for core facilities must use Case Comprehensive Cancer Center cores, when available, rather than cores at institutions outside Cleveland.

View detailed instructions: [gu-malignancies-instructions-2017]

Contact casecccpilots@case.edu or Megan Kilbane at 216.286.4440 with any questions.

Request for Proposals for Case CCC Funding for Pilot/Phase I Clinical Trials

The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions.

The proposals are being accepted on a rolling basis subject to availability of funds.

Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office, katarzyna.karelus@case.edu, 216.844.4176.